A pilot study of pembrolizumab and exemestane/leuprolide in premenopausal hormone receptor positive/HER2 negative locally advanced or metastatic breast cancer (PEER).

被引：0

作者：

Chen, I-Chun ^{[1
]}

Lin, Ching-Hung ^{[1
]}

Chang, Dwan-Ying ^{[2
]}

Chen, Tom Wei-Wu ^{[2
]}

Wang, Ming-Yang ^{[1
]}

Ma, Wei-Li ^{[2
]}

Lin, Yi-Ting ^{[2
]}

Huang, Shu-Min ^{[2
]}

Lu, Yen-Shen ^{[2
]}

机构：

[1] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan

[2] Natl Taiwan Univ Hosp, Taipei, Taiwan

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT028

引用

页数：1

共 50 条

[31] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit, Mariya
Mun, Sophia
Soulos, Pamela
Adelson, Kerin
Pusztai, Lajos
Mougalian, Sarah
BREAST CANCER RESEARCH, 2021, 23 (01)
[32] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Mariya Rozenblit
Sophia Mun
Pamela Soulos
Kerin Adelson
Lajos Pusztai
Sarah Mougalian
Breast Cancer Research, 23
[33] Treatment options for hormone receptor positive, HER-2 negative metastatic breast cancer
Woeckel, Achim
Bauerfeind, Ingo
Fehm, Tanja
Janni, Wolfgang
Mueller, Volkmar
Thill, Marc
Thomssen, Christoph
Untch, Michael
Witzel, Isabell
Schneeweiss, Andreas
GYNAKOLOGE, 2020, 53 (11): : 780 - 783
[34] Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort
Novik, Y.
Klar, N.
Zamora, S.
Kwa, M.
Speyer, J.
Oratz, R.
Muggia, F.
Meyers, M.
Hochman, T.
Goldberg, J.
Adams, S.
ANNALS OF ONCOLOGY, 2020, 31 : S59 - S59
[35] Utility of oncotype in premenopausal women with hormonal receptor (hr) positive her2 negative early breast cancer
Cudos, A. Gasol
Murillo, S. Morales
Der-Abrain, N. Tuset
Guzman, D. R. Sanchez
Villellas, F. Vilardell
Orillo, E. Morera M.
Morales, C. Canosa
Olive, J. Mele
Cid, L. Arbones
BREAST, 2023, 68 : S19 - S19
[36] Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alvarado-Miranda, Alberto
Lara-Medina, Fernando Ulises
Munoz-Montano, Wendy R.
Zinser-Sierra, Juan W.
Galeana, Paula Anel Cabrera
Garza, Cynthia Villarreal
Benitez, Daniel Sanchez
Rodriguez, Jesus Alberto Limon
Salinas, Claudia Haydee Arce
Guijosa, Alberto
Arrieta, Oscar
CURRENT ONCOLOGY, 2023, 30 (07) : 6097 - 6110
[37] Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Shah, Ami N.
Flaum, Lisa
Helenowski, Irene
Santa-Maria, Cesar A.
Jain, Sarika
Rademaker, Alfred
Nelson, Valerie
Tsarwhas, Dean
Cristofanilli, Massimo
Gradishar, William
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[38] Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021
Mezni, Essia
Sabatier, Renaud
Goncalves, Anthony
Vicier, Cecile
BULLETIN DU CANCER, 2022, 109 (02) : 216 - 225
[39] Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
Wang, Changjun
Lin, Yan
Zhou, Yidong
Mao, Feng
Zhu, Hanjiang
Guan, Jinghong
Zhang, Xiaohui
Shen, Songjie
Huang, Xin
Chen, Chang
Yao, Ru
Zhao, Jialin
Sun, Qiang
BMC CANCER, 2020, 20 (01)
[40] Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
Changjun Wang
Yan Lin
Yidong Zhou
Feng Mao
Hanjiang Zhu
Jinghong Guan
Xiaohui Zhang
Songjie Shen
Xin Huang
Chang Chen
Ru Yao
Jialin Zhao
Qiang Sun
BMC Cancer, 20

← 1 2 3 4 5 →